$Immix Biopharma (IMMX.US)$ NEWS Immix Biopharma Awarded Eur...
NEWS
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
Immix Biopharma, Inc. has been granted European Orphan Drug Designation for NXC-201 in the treatment of multiple myeloma, providing 10 years of market exclusivity, access to centralized authorization procedure, and reduced fees for various applications. The Company aims to address unmet medical needs in frail patients with relapsed/refractory multiple myeloma, with potential benefits in terms of tolerability and clinical impact. The designation signifies recognition of the therapy's potential for this patient population, opening up opportunities for further development.
Granting of European Orphan Drug Designation for NXC-201 in multiple myeloma, showcasing potential clinical impact and addressing unmet medical needs in frail patients.
Potential for NXC-201 to provide an attractive treatment option for frail relapsed/refractory multiple myeloma patients, along with expansion into other autoimmune diseases.
Recognition of NXC-201's favorable tolerability profile and 'Single Day CRS' across a robust clinical dataset, indicating promising therapeutic potential.
Potential for NXC-201 to provide an attractive treatment option for frail relapsed/refractory multiple myeloma patients, along with expansion into other autoimmune diseases.
Recognition of NXC-201's favorable tolerability profile and 'Single Day CRS' across a robust clinical dataset, indicating promising therapeutic potential.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
729Followers
75Following
4657Visitors
Follow